Literature DB >> 16100478

Detection of bone marrow metastases by FDG-PET and missed by bone scintigraphy in widespread melanoma.

Aysel Aydin1, Jian Q Yu, Hongming Zhuang, Abass Alavi.   

Abstract

The optimal management of patients with melanoma requires accurate imaging techniques that can screen the entire body for metastases. One of the most used tests for this purpose is bone scintigraphy. PET has been reported to be more sensitive than bone scintigraphy in some malignancies. In our case, FDG-PET was also superior to bone scintigraphy in detecting the extent of skeletal disease in a patient with melanoma. This is likely the result of the fact that metastasis to bone marrow may not result in bone reaction in certain conditions and therefore bone scans may remain negative despite skeletal involvement.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16100478     DOI: 10.1097/01.rlu.0000174200.67064.28

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  4 in total

1.  Sinonasal malignant melanoma with diffuse carcinomatosis: initial PET/CT staging and follow-up CT/MR imaging.

Authors:  Ba D Nguyen
Journal:  Radiol Case Rep       Date:  2015-11-06

2.  3D skeletal uptake of 18F sodium fluoride in PET/CT images is associated with overall survival in patients with prostate cancer.

Authors:  Sarah Lindgren Belal; May Sadik; Reza Kaboteh; Nezar Hasani; Olof Enqvist; Linus Svärm; Fredrik Kahl; Jane Simonsen; Mads H Poulsen; Mattias Ohlsson; Poul F Høilund-Carlsen; Lars Edenbrandt; Elin Trägårdh
Journal:  EJNMMI Res       Date:  2017-02-16       Impact factor: 3.138

Review 3.  Staging of cutaneous melanoma.

Authors:  P Mohr; A M M Eggermont; A Hauschild; A Buzaid
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

4.  Diagnostic Role of (18)F-FECH-PET/CT Compared with Bone Scan in Evaluating the Prostate Cancer Patients Referring with Biochemical Recurrence.

Authors:  Mustafa Takesh; Khaldoun Odat Allh; Stefan Adams; Christian Zechmann
Journal:  ISRN Oncol       Date:  2012-11-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.